Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Mar 1;7(2):500-19.
doi: 10.1177/193229681300700227.

Continuous glucose monitoring: evidence and consensus statement for clinical use

Andreas Liebl  1 , Helmut R Henrichs, Lutz Heinemann, Guido Freckmann, Eberhard Biermann, Andreas Thomas; Continuous Glucose Monitoring Working Group of the Working Group Diabetes Technology of the German Diabetes Association
Affiliations
Review

Continuous glucose monitoring: evidence and consensus statement for clinical use

Andreas Liebl et al. J Diabetes Sci Technol. .

Abstract

Continuous glucose monitoring (CGM) is an essential tool for modern diabetes therapy. Randomized controlled studies have provided evidence that hemoglobin A1c (HbA1c) results can be improved in patients with type 1 diabetes with elevated baseline HbA1c when using CGM frequently enough and that the frequency and duration of hypoglycemic events can be reduced in patients with satisfactory baseline HbA1c. The CGM group within the Working Group Diabetes Technology (AGDT) of the German Diabetes Association (DDG) has defined evidence-based indications for the practical use of CGM in this consensus statement related to hypoglycemia (frequent, severe, or nocturnal) or hypoglycemia unawareness, insufficient metabolic control despite use of all possible therapeutic options and patient compliance, pregnancy associated with inadequate blood glucose results, and the need for more than 10 blood glucose measurements per day. Contraindications and defined preconditions for the successful use of CGM should be considered.

PubMed Disclaimer

Figures

Figure 1
Figure 1
General differences in the use of CGM systems.
Figure 2
Figure 2
Changes in metabolic control (reduction in HbA1c compared with the baseline value) and in the hypoglycemic frequency in randomized, controlled studies (marked with appropriate colors) with usage of CGM systems, in some cases also with SaP therapy.,– The data relate to the change in hypoglycemic frequency, not direct values. (Details of studies: duration in months, year of publication, number of patients with preexisting insulin pump therapy, number of patients with sensor-augmented insulin pump therapy [adjustment to this option in the study])
See this image and copyright information in PMC

References

    1. Mauras N, Fox L, Englert K, Beck RW. Continuous glucose monitoring in type 1 diabetes. Endocrine. 2013;43(1):41–50. - PubMed
    1. Siegmund T, Kolassa R, Thomas A. London: Unimed Science Verlag Bremen; 2012. Continuous glucose monitoring (CGM) und sensor-augmented pump therapy (SAP)
    1. Rebrin K, Steil GM, van Antwerp WP, Mastrototaro JJ. Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring. Am J Physiol. 1999;277(3 Pt 1):E561–71. - PubMed
    1. Vaddiraju S, Burgess DJ, Tomazos I, Jain FC, Papadimitrakopoulos F. Technologies for continuous glucose monitoring: Current problems and future promises. J Diabetes Sci Technol. 2010;4(6):1540–62. - PMC - PubMed
    1. Freckmann G, Schmid C, Baumstark A, Pleus S, Link M, Haug C. System accuracy evaluation of 43 blood glucose monitoring systems for self-monitoring of blood glucose according to DIN EN ISO 15197. J Diabetes Sci Technol. 2012;6(5):1060–75. - PMC - PubMed